T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.47B |
| 2 |
NXP Semiconductors
NXPI
|
+$1.73B |
| 3 |
Tesla
TSLA
|
+$1.7B |
| 4 |
Northrop Grumman
NOC
|
+$1.67B |
| 5 |
Dollar Tree
DLTR
|
+$1.6B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$3.29B |
| 2 |
Meta Platforms (Facebook)
META
|
+$1.85B |
| 3 |
Texas Instruments
TXN
|
+$1.82B |
| 4 |
Microsoft
MSFT
|
+$1.27B |
| 5 |
Booking.com
BKNG
|
+$1.18B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.76% |
| 2 | Technology | 16.79% |
| 3 | Consumer Discretionary | 15.26% |
| 4 | Financials | 14.49% |
| 5 | Industrials | 9.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
AXON
1351
Axon Enterprise
AXON
$50B
| $10.8M | ﹤0.01% |
158,311
+3,693
| +2% | +$249K |
|
|
DOCU
1352
DocuSign
DOCU
$12.2B
| $10.7M | ﹤0.01% |
204,268
-20,188
| -9% | -$1.14M |
|
1353
Tandem Diabetes Care
TNDM
$1.61B
| $10.6M | ﹤0.01% |
+246,892
| New | +$8.62M |
|
|
FTSV
1354
DELISTED
Forty Seven, Inc. Common Stock
FTSV
| $10.5M | ﹤0.01% |
706,576
+4,576
| +0.7% | +$68.2K |
|
1355
Dick's Sporting Goods
DKS
$18.1B
| $10.5M | ﹤0.01% |
296,944
+206,651
| +229% | +$7.41M |
|
1356
Aaon
AAON
$7.23B
| $10.5M | ﹤0.01% |
416,376
-34,046
| -8% | -$873K |
|
1357
Xerox
XRX
$412M
| $10.4M | ﹤0.01% |
385,740
+4,830
| +1% | +$128K |
|
|
NEWR
1358
DELISTED
New Relic, Inc.
NEWR
| $10.4M | ﹤0.01% |
109,943
+54,891
| +100% | +$5.69M |
|
1359
Denali Therapeutics
DNLI
$3.97B
| $10.3M | ﹤0.01% |
476,067
+112,242
| +31% | +$1.86M |
|
|
YMAB
1360
DELISTED
Y-mAbs Therapeutics
YMAB
| $10.3M | ﹤0.01% |
+389,400
| New | +$9.9M |
|
1361
Dell
DELL
$320B
| $10.3M | ﹤0.01% |
376,966
+7,159
| +2% | +$191K |
|
1362
AngioDynamics
ANGO
$647M
| $10.3M | ﹤0.01% |
472,214
-10,082
| -2% | -$224K |
|
|
MDSO
1363
DELISTED
Medidata Solutions, Inc.
MDSO
| $10.2M | ﹤0.01% |
139,761
-1,173
| -0.8% | -$93.8K |
|
|
HBI
1364
DELISTED
Hanesbrands
HBI
| $10.2M | ﹤0.01% |
551,860
-13,215,800
| -96% | -$256M |
|
|
HTGM
1365
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
| $10.1M | ﹤0.01% |
11,108
-5
| -0% | -$3.3K |
|
|
CLDR
1366
DELISTED
Cloudera, Inc.
CLDR
| $10.1M | ﹤0.01% |
570,420
-160,046
| -22% | -$2.43M |
|
1367
BBVA Argentina
BBAR
$3.27B
| $10M | ﹤0.01% |
861,060
+488,710
| +131% | +$5.55M |
|
1368
H&R Block
HRB
$6.76B
| $9.98M | ﹤0.01% |
387,772
| – | – |
|
1369
Central Garden & Pet Co Class A
CENTA
$2.41B
| $9.94M | ﹤0.01% |
374,945
+341,302
| +1,014% | +$10.3M |
|
|
NFX
1370
DELISTED
Newfield Exploration
NFX
| $9.83M | ﹤0.01% |
341,006
+13
| +0% | +$366 |
|
|
PBCT
1371
DELISTED
People's United Financial Inc
PBCT
| $9.77M | ﹤0.01% |
570,831
+39,600
| +7% | +$724K |
|
1372
Leggett & Platt
LEG
$1.32B
| $9.75M | ﹤0.01% |
222,666
| – | – |
|
1373
Ichor Holdings
ICHR
$2.67B
| $9.7M | ﹤0.01% |
474,864
+3,265
| +0.7% | +$71.6K |
|
1374
Williams-Sonoma
WSM
$28.5B
| $9.68M | ﹤0.01% |
294,424
-176
| -0.1% | -$5.58K |
|
1375
MongoDB
MDB
$38B
| $9.6M | ﹤0.01% |
117,773
+43,451
| +58% | +$2.9M |
|
Similar funds
T. Rowe Price Associates's Q3 2018 Portfolio in Review
As of Q3 2018, T. Rowe Price Associates held 2,658 positions worth $685B, up 4.7% from $654B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
T. Rowe Price Associates's Q3 2018 filing shows 77 new, 1,268 increased, 1,098 reduced and 77 closed positions. Its largest new stake was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M. The largest sale was Broadcom, an estimated $3.29B.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- T. Rowe Price Associates's largest Q3 2018 buy was Fortive Corporation 5.00% Mandatory Convertible Preferred Stock, Series A: 194,161 shares worth $208M.
- T. Rowe Price Associates added most to NVIDIA in Q3 2018, an estimated $2.47B increase.
- T. Rowe Price Associates's biggest Q3 2018 reduction was Broadcom, cutting an estimated $3.29B.
- T. Rowe Price Associates fully exited DCT Industrial Trust Inc. in Q3 2018, selling an estimated $345M.
- T. Rowe Price Associates's ten largest holdings make up 20% of its $685B portfolio in Q3 2018.
- T. Rowe Price Associates opened 77 new positions and closed 77 in Q3 2018.
- T. Rowe Price Associates's portfolio value rose 4.7% quarter-over-quarter to $685B.
Based on T. Rowe Price Associates's 13F filing for Q3 2018, filed 14 Nov 2018.